Sarepta has launched a new additional Phase III trial for Elevidys (Roche-licensed) after the European Medicines Agency denied marketing authorization in 2025 for failing to meet efficacy endpoints in movement abilities at 12 months. The new registration-enabling study is designed to address EMA concerns with placebo-controlled data over 72 weeks, with Roche overseeing the trial.